Aggressive CD8(+) epidermotropic cutaneous T-cell lymphoma associated with homozygous mutation in SAMHD1.

JAAD Case Rep

Department of Dermatology, Case Western Reserve University School of Medicine, UH Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio.

Published: July 2015

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808729PMC
http://dx.doi.org/10.1016/j.jdcr.2015.05.003DOI Listing

Publication Analysis

Top Keywords

aggressive cd8+
4
cd8+ epidermotropic
4
epidermotropic cutaneous
4
cutaneous t-cell
4
t-cell lymphoma
4
lymphoma associated
4
associated homozygous
4
homozygous mutation
4
mutation samhd1
4
aggressive
1

Similar Publications

Castration-resistant prostate cancer (CRPC) presents significant therapeutic challenges due to its aggressive nature and poor prognosis. Targeting Aurora-A kinase (AURKA) has shown promise in cancer treatment. This study investigates the efficacy of ART-T cell membrane-encapsulated AMS@AD (CM-AMS@AD) nanoparticles (NPs) in a photothermal-chemotherapy-immunotherapy combination for CRPC.

View Article and Find Full Text PDF

Thermosensitive hydrogel delivery of BCG lysates and tumor antigens: A novel strategy for melanoma immunoprevention and therapeutics.

Biochem Biophys Res Commun

December 2024

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address:

Melanoma, recognized as one of the most aggressive forms of skin cancer, continues to show a steady rise in global incidence. While Bacillus Calmette-Guérin (BCG) has been identified as a potential intralesional therapy for melanoma, its therapeutic efficacy remains suboptimal. This study introduces a novel thermosensitive hydrogel formulated with BCG lysates and either OVA peptide or tumor cell lysates (PPP-BCG-OVA/TL).

View Article and Find Full Text PDF

The importance of collagen and elastin remains incompletely understood concerning tumor immunity in cancer tissues. This study explored the clinical significance of collagen and elastin deposition on tumor immunity in advanced colorectal cancer patients. The collagen and elastin contents were assessed simultaneously using elastic van Gieson (EVG) histochemical staining.

View Article and Find Full Text PDF

Galectin-3 secreted by triple-negative breast cancer cells regulates T cell function.

Neoplasia

December 2024

Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel; Tel Aviv University, Faculty of Medicine and Health Sciences, Tel Aviv, Israel; Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel; Davidoff Cancer Center, Beilinson Campus, Petah Tikva, Israel. Electronic address:

Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 10-15 % of breast cancer. Current treatment of high-risk early-stage TNBC includes neoadjuvant chemo-immune therapy. However, the substantial variation in immune response prompts an urgent need for new immune-targeting agents.

View Article and Find Full Text PDF

Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.

Front Immunol

December 2024

SAMRC Precision Oncology Research Unit (PORU), DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP), Pan African Cancer Research Institute (PACRI), University of Pretoria, Hatfield, South Africa.

Malignant melanoma, the most aggressive form of skin cancer, is characterized by unpredictable growth patterns, and its mortality rate has remained alarmingly high over recent decades, despite various treatment approaches. One promising strategy for improving outcomes in melanoma patients lies in the early use of biomarkers to predict prognosis. Biomarkers offer a way to gauge patient outlook early in the disease course, facilitating timely, targeted intervention.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!